Similarly, although RAF inhibitors alone have shown limited success in KRAS-mutant CRC, combination strategies targeting RAF and MEK or RAF and EGFR are being explored to suppress MAPK signaling and potentially overcome resistance (Table 3). This evidence concerns the gene EGFR and colorectal carcinoma.